Pharma is opening the doors for external molecule designers
The Open Innovation model is being explored by Pharma and it holds great promise for all parties in the Life Science ecosystem. In a move to further boost early drug discovery innovation several OI platforms in Pharma RnD have been established in order to allow external partner to much more easily test their molecules for biological activity.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>